These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 7820609)

  • 1. Axonal transport of manganese and its relevance to selective neurotoxicity in the rat basal ganglia.
    Sloot WN; Gramsbergen JB
    Brain Res; 1994 Sep; 657(1-2):124-32. PubMed ID: 7820609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zinc transport from the striatum and substantia nigra.
    Takeda A; Kodama Y; Ohnuma M; Okada S
    Brain Res Bull; 1998 Sep; 47(1):103-6. PubMed ID: 9766396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Manganese transport in the neural circuit of rat CNS.
    Takeda A; Kodama Y; Ishiwatari S; Okada S
    Brain Res Bull; 1998; 45(2):149-52. PubMed ID: 9443831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective lesions by manganese and extensive damage by iron after injection into rat striatum or hippocampus.
    Sloot WN; van der Sluijs-Gelling AJ; Gramsbergen JB
    J Neurochem; 1994 Jan; 62(1):205-16. PubMed ID: 7505311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model.
    Rosenblad C; Kirik D; Björklund A
    Exp Neurol; 2000 Feb; 161(2):503-16. PubMed ID: 10686072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Axonal transport of proteins and glycoproteins in the rat nigro-striatal pathway and the effects of 6-hydroxydopamine.
    Roger LJ; Breese GR; Morell P
    Brain Res; 1980 Sep; 197(1):95-112. PubMed ID: 6156743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrastriatal quinolinic acid injections protect against 6-hydroxydopamine-induced lesions of the dopaminergic nigrostriatal system.
    Venero JL; Romero-Ramos M; Revuelta M; Machado A; Cano J
    Brain Res; 1995 Feb; 672(1-2):153-8. PubMed ID: 7749737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat.
    Herkenham M; Lynn AB; de Costa BR; Richfield EK
    Brain Res; 1991 May; 547(2):267-74. PubMed ID: 1909204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 6-Hydroxydopamine-lesioning of the nigrostriatal pathway in rats alters basal ganglia mRNA for copper, zinc- and manganese-superoxide dismutase, but not glutathione peroxidase.
    Kunikowska G; Jenner P
    Brain Res; 2001 Dec; 922(1):51-64. PubMed ID: 11730701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo biosynthesis of [35S]- and [3H]substance P in the striatum of the rat and their axonal transport to the substantia nigra.
    Krause JE; Reiner AJ; Advis JP; McKelvy JF
    J Neurosci; 1984 Mar; 4(3):775-85. PubMed ID: 6200582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The neostriatal mosaic. I. Compartmental organization of projections from the striatum to the substantia nigra in the rat.
    Gerfen CR
    J Comp Neurol; 1985 Jun; 236(4):454-76. PubMed ID: 2414339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long distance directed axonal growth from human dopaminergic mesencephalic neuroblasts implanted along the nigrostriatal pathway in 6-hydroxydopamine lesioned adult rats.
    Wictorin K; Brundin P; Sauer H; Lindvall O; Björklund A
    J Comp Neurol; 1992 Sep; 323(4):475-94. PubMed ID: 1358925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time- and dose-dependent 45Ca2+ accumulation in rat striatum and substantia nigra after an intrastriatal injection of quinolinic acid.
    Gramsbergen JB; van der Sluijs-Gelling AJ
    Exp Neurol; 1993 Jun; 121(2):261-9. PubMed ID: 8339777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behavioral effects of manganese injected in the rat substantia nigra are potentiated by dicumarol, a DT-diaphorase inhibitor.
    Díaz-Véliz G; Mora S; Gómez P; Dossi MT; Montiel J; Arriagada C; Aboitiz F; Segura-Aguilar J
    Pharmacol Biochem Behav; 2004 Feb; 77(2):245-51. PubMed ID: 14751451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabinoid effects in basal ganglia in a rat model of Parkinson's disease.
    Sañudo-Peña MC; Patrick SL; Khen S; Patrick RL; Tsou K; Walker JM
    Neurosci Lett; 1998 Jun; 248(3):171-4. PubMed ID: 9654336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Organization of striatopallidal, striatonigral, and nigrostriatal projections in the macaque.
    Hedreen JC; DeLong MR
    J Comp Neurol; 1991 Feb; 304(4):569-95. PubMed ID: 2013650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration.
    Connor B; Kozlowski DA; Unnerstall JR; Elsworth JD; Tillerson JL; Schallert T; Bohn MC
    Exp Neurol; 2001 May; 169(1):83-95. PubMed ID: 11312561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of behavioural abnormalities by fetal allografts in a novel rat model of striatonigral degeneration.
    Wenning GK; Granata R; Laboyrie PM; Quinn NP; Jenner P; Marsden CD
    Mov Disord; 1996 Sep; 11(5):522-32. PubMed ID: 8866493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substantia nigra glutamate antagonists produce contralateral turning and basal ganglia Fos expression: interactions with D1 and D2 dopamine receptor agonists.
    McPherson RJ; Marshall JF
    Synapse; 2000 Jun; 36(3):194-204. PubMed ID: 10819899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of immediate early gene proteins following axotomy and inhibition of axonal transport in the rat central nervous system.
    Leah JD; Herdegen T; Murashov A; Dragunow M; Bravo R
    Neuroscience; 1993 Nov; 57(1):53-66. PubMed ID: 8278059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.